Leadership Overview
Telix has 8 executives leading key functions including strategy, technology, information, finance, operations, and medicine.
Driven by innovation in cancer treatment, Telix specializes in developing and commercializing diagnostic and therapeutic radiopharmaceuticals, leveraging molecularly targeted radiation to image and treat cancer, thereby advancing precision medicine globally.
Driven by innovation in cancer treatment, Telix specializes in developing and commercializing diagnostic and therapeutic radiopharmaceuticals, leveraging molecularly targeted radiation to image and treat cancer, thereby advancing precision medicine globally.
Leadership Roles at Telix
Anthony Galla - Chief Executive Officer
Anthony Galla, the Chief Executive Officer at Telix, directs the company's overarching strategy and global operations. Galla oversees the expansion of Telix's theranostics portfolio, focusing on urologic oncology, neuro-oncology, and musculoskeletal oncology. This leadership role involves guiding the commercialization efforts for key products like Illuccix, ensuring regulatory approvals across major markets such as the FDA, TGA, and Health Canada are secured and maintained. Anthony Galla drives the company's mission to deliver innovative cancer imaging and treatment solutions, fostering collaborations with research institutions and healthcare providers worldwide. The Chief Executive Officer's responsibilities extend to capital allocation, investor relations, and setting the strategic direction for future pipeline development, ultimately impacting Telix's market position in the biopharmaceutical sector.
Shomalin Naidoo - Chief Financial Officer, Therapeutics, International Business, Corporate
Shomalin Naidoo, the Chief Financial Officer, Therapeutics, International Business, Corporate at Telix, oversees the financial strategy for the company's therapeutic divisions and international operations. Naidoo manages financial planning, budgeting, and reporting, ensuring fiscal discipline across global business units. This role involves analyzing market opportunities and financial performance in key international regions, supporting the commercialization of products like Illuccix. The Chief Financial Officer, Therapeutics, International Business, Corporate's responsibilities extend to managing corporate finance, including treasury functions and investor relations support for international stakeholders. Shomalin Naidoo's financial acumen is crucial for driving sustainable growth and profitability in Telix's expanding global footprint, particularly in the complex regulatory environments of international markets.
Darren Smith - Group Chief Financial Officer
Darren Smith, the Group Chief Financial Officer at Telix, directs the overall financial health and strategic financial planning for the entire organization. Smith oversees all aspects of financial management, including accounting, financial reporting, treasury, and capital markets activities. This leadership position involves ensuring compliance with global financial regulations and optimizing the company's capital structure to support its growth objectives. The Group Chief Financial Officer's responsibilities are critical for maintaining investor confidence and securing funding for Telix's extensive research and development pipeline and commercial expansion. Darren Smith's strategic financial oversight is fundamental to Telix's ability to execute its mission of developing and commercializing innovative radiopharmaceuticals worldwide.
Christopher Nicholas - Chief Financial Officer, Precision Medicine, Tms & Medtech
Christopher Nicholas, the Chief Financial Officer, Precision Medicine, Tms & Medtech at Telix, manages the financial operations specifically for the company's precision medicine, therapeutic medical systems, and medical technology segments. Nicholas is responsible for financial analysis, forecasting, and resource allocation within these specialized areas, ensuring alignment with strategic objectives. This role involves close collaboration with R&D and commercial teams to support product development and market entry strategies for innovative theranostic solutions. The Chief Financial Officer, Precision Medicine, Tms & Medtech's financial guidance is essential for optimizing investments in cutting-edge technologies and ensuring the economic viability of Telix's precision medicine initiatives. Christopher Nicholas's financial expertise directly supports the advancement of targeted cancer therapies and diagnostic tools.
Darren Patti - Group Chief Operating Officer
Darren Patti, the Group Chief Operating Officer at Telix, oversees the company's global operational functions, ensuring efficiency and scalability across all business units. Patti directs manufacturing, supply chain management, and quality assurance, critical components for the reliable production of radiopharmaceuticals. This leadership role involves optimizing production processes to meet global demand for Telix's diagnostic and therapeutic agents, including Illuccix. The Group Chief Operating Officer's responsibilities extend to managing operational infrastructure, implementing best practices, and ensuring compliance with international regulatory standards. Darren Patti's operational expertise is fundamental to Telix's ability to deliver life-changing cancer treatments to patients worldwide, driving operational excellence from development through to commercial distribution.
Paul Schaffer - Chief Technology Officer
Paul Schaffer, the Chief Technology Officer at Telix, architects the technological infrastructure supporting the company's radiopharmaceutical development. Schaffer leads the innovation pipeline, focusing on advancing the science behind theranostics and ensuring the efficacy and safety of Telix's diagnostic and therapeutic agents. This involves overseeing research and development initiatives, particularly in areas like PSMA-PET/CT imaging for prostate cancer. The Chief Technology Officer's role is critical in translating scientific discoveries into commercially viable products, managing intellectual property, and ensuring compliance with stringent industry regulations. Paul Schaffer drives the technological advancements necessary for Telix to maintain its competitive edge in the rapidly evolving biopharmaceutical landscape, impacting the development of treatments for urologic oncology and other critical disease areas.
Craig Ulrick - Chief Information Officer
Craig Ulrick, the Chief Information Officer at Telix, manages the company's global information technology strategy and infrastructure. Ulrick ensures the secure and efficient operation of all IT systems, supporting Telix's research, development, and commercial activities. This includes implementing robust data management solutions for clinical trials and product development, safeguarding sensitive patient and corporate information. The Chief Information Officer's responsibilities encompass cybersecurity, digital transformation initiatives, and the integration of advanced technologies to enhance operational efficiency across the organization. Craig Ulrick plays a vital part in enabling Telix's mission by providing the technological backbone required for its biopharmaceutical operations, from drug discovery to market delivery, ensuring seamless data flow and system reliability.
David Cade - Chief Medical Officer
David Cade, the Chief Medical Officer at Telix, leads the company's clinical development strategy and medical affairs. Cade oversees the design and execution of clinical trials for Telix's pipeline of diagnostic and therapeutic radiopharmaceuticals, focusing on areas such as urologic oncology and neuro-oncology. This critical role involves ensuring that clinical programs meet rigorous scientific and regulatory standards, advancing the understanding and application of theranostics. The Chief Medical Officer's responsibilities include engaging with the medical community, providing clinical insights, and guiding the interpretation of clinical data to support product approvals and market adoption. David Cade's medical leadership is instrumental in translating Telix's scientific innovations into effective cancer treatments for patients globally.
Explore Leadership Teams in Manufacturing
Emcure Pharmaceuticals Limited is a global pharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products and healthcare solutions. Headquartered in Pune, India, the organization operates as an international pharmaceutical enterprise with a strong presence in both domestic and global healthcare markets. The company focuses on delivering innovative and affordable medicines that address a wide spectrum of medical conditions and therapeutic needs across the healthcare sector. The organization is driven by a research-focused strategy that emphasizes innovation, scientific advancement, and the development of effective therapeutic solutions. Through its research and development capabilities, Emcure Pharmaceuticals works to discover and formulate medicines that address unmet medical needs and improve patient outcomes. The company’s research initiatives focus on areas such as complex generics, biosimilars, biologics, and specialized pharmaceutical formulations. These research efforts allow the organization to continuously introduce improved therapies and drug delivery systems designed to enhance treatment effectiveness and patient safety.
Company Leadership SM
NS
Zai Lab functions as a bio-pharmaceutical and drug discovery company with a focus in oncology and autoimmune diseases. The company was established in 2014 and is headquartered out of Shanghai, China.
Company Leadership KL
HR
DL
JS
Акрихин is a leading Russian pharmaceutical company that has been producing effective, affordable, and high-quality medications since 1936. The company offers a diverse portfolio of over 200 socially significant pharmaceutical products, including prescription and over-the-counter drugs. With a strong focus on research and development, Акрихин actively invests in creating new medications and adheres to international GMP standards in all stages of production. The company aims to serve a wide range of clients, including healthcare professionals and patients in need of reliable medical treatments.
Company Leadership AT
KP
BT
Founded in 1987, Integrated DNA Technologies, Inc. headquartered in Coralville, Iowa, is the supplier of custom nucleic acids, serving the areas of academic research, biotechnology, clinical diagnostics, and pharmaceutical development. The company develops, manufactures, and markets nucleic acid products for the life sciences industry.
Company Leadership AA
CL
AG
AM
Frequently Asked Questions Regarding Telix Top Executives and Leadership Team
Unlock more people and company data
